Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas

(ASPIRIN)

Summary:
A project in collaboration with Columbia University, with funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), USA

Principal Investigator: Dr Sarah Saleem
Co-Investigator: Dr Saleem Jessani

ABSTRACT

Background:
Preterm birth (PTB) remains the leading cause of neonatal mortality and long term disability throughout the world. Though complex in its origins, a growing body of evidence suggests that first trimester administration of low dose aspirin (LDA) holds promise to reduce the rate of PTB substantially.

Hypothesis:
First trimester administration of aspirin will reduce the risk of preterm birth.

Study Design Type:
Prospective randomized, placebo-controlled, double-blinded multicenter clinical trial. Trial will be individually randomized with one-to-one ratio (intervention/control)

Population:
Nulliparous women between the ages of 18 and 40, with a singleton pregnancy between 6 0/7 weeks and 13 6/7 weeks gestational age (GA) confirmed by ultrasound prior to enrollment, no more than two previous first trimester pregnancy losses, and no contraindications to aspirin. Minors who are ≥ 14 years of age may be enrolled if permitted by the country’s ethical guidelines.

Intervention:
Daily administration of low dose (81 mg) aspirin, initiated between 6 0/7 weeks and 13 6/7 weeks GA and continued to 36 0/7 weeks GA, compared to an identical appearing placebo. Compliance and outcomes will be assessed biweekly.

Outcomes
Primary: To determine whether daily LDA initiated between 6 0/7 -13 6/7 weeks GA and continued to 36 0/7 weeks GA reduces the risk of PTB (birth prior to 37 0/7 weeks GA).
Secondary: of interest are the rate of preeclampsia/eclampsia, small for gestational age (SGA), and perinatal mortality.